Please assess the completion status of the following clinical trial:

Trial Title: MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Previous diagnosis of MM based on standard criteria as defined in Appendix A (Diagnostic Criteria for MM). Diagnostic studies need not be performed within 30 days of registration;~2. Patients must meet one of the disease criteria outlined in either a, b, or c:~   a. Patients with newly diagnosed high-risk MM achieving a partial response (PR) or better at the time of enrollment in response to systemic anti-myeloma therapy, which may include autologous hematopoietic stem cell transplant (HSCT).~   High risk is defined by the presence of any one of the following:~   i. High-risk chromosomal translocations by fluorescent in situ hybridization (FISH): t(4;14), t(14;16), t(14;20), del(17p), del(1p), amplification 1q ii. Myeloma Prognostic Risk Signature 70-Gene expression profiling (MyPRS GEP-70) high-risk signature either at diagnosis or at time of registration for the study iii. Lactate dehydrogenase (LDH) \> 300 U/L at diagnosis iv. Plasma cell leukemia v. Relapse from prior therapy within 12 months~   b. Patients with high-risk MM with at least 1 prior progression in PR or better in response to salvage systemic anti-myeloma therapy at the time of enrollment~   c. Patients with standard risk MM with 1 prior progression within 18 months from an autologous HSCT and in very good partial remission (VGPR) or better in response to salvage systemic anti-myeloma therapy at the time of enrollment.~3. Patients must have a suitable first-degree or second-degree related, Human leukocyte antigen (HLA)-haploidentical or HLA-matched stem cell donor. The donor and recipient must be identical at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, major histocompatibility complex, class II, DR beta 1 (HLA-DRB1), and Major Histocompatibility Complex, Class II, DQ Beta 1 (HLA-DQB1). A minimum match of 5/10 is therefore required, and will be considered sufficient evidence that the donor and recipient share one HLA haplotype;~4. No previous AlloSCT (syngeneic HSCT permissible);~5. Any previous autologous HSCT must have occurred at least 3 months prior to start of conditioning;~6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;~7. Life expectancy \> 6 months;~8. Adequate end organ function as measured by:~   1. Left ventricular ejection fraction ≥ 35% or shortening fraction \> 25%~  2. Bilirubin ≤ 3.0 mg/dL (unless due to Gilbert's syndrome or hemolysis), and alanine aminotransferase (ALT) and aspartate transaminase (AST) \< 5x upper limit of normal (ULN)~  3. Forced expiratory volume at one second (FEV1) and forced vital capacity (FVC) \> 40% of predicted~9. Not pregnant or breast-feeding;~10. No uncontrolled infection. Note: Infection is permitted if there is evidence of response to medication;~11. The patient must be able to comprehend and have signed the informed consent.~Exclusion Criteria:~1. Diagnosis of any of the following cancers:~   1. POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes)~  2. Non-secretory myeloma (no measurable protein on Serum Free Lite Assay)~  3. HTLV1 / HTLV2 positive~  4. Diagnosis of amyloidosis~2. Failed to achieve at least a partial response (PR) to latest therapy;~3. Known history of HIV infection;~4. Systemic infection requiring treatment with antibiotics, antifungal, or antiviral agents within 7 days of registration;~5. History of malignancy other than MM within 5 years of registration, except adequately treated basal or squamous cell skin cancer;~6. History of serious allergy or reaction to any component of the MEDI-551 formulation that would prevent administration;~7. Active hepatitis B as defined by seropositivity for hepatitis B surface antigen or patients with positive hepatitis B core antibody titers.~8. Patients with hepatitis C antibody will be eligible provided that they do not have elevated liver transaminases or other evidence of active hepatitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MEDI-551 Treatment Arm (Type: EXPERIMENTAL): Medi-551 maintenance therapy will be initiated on Day 60, Day 90, or Day 120 of NM-AlloSCT based on the eligibility criteria for the initiation of maintenance therapy as described in Section 3.1. MEDI-551 will be administered on 28-day cycles at a dose of 4mg/kg, as an IV infusion over 60 ±15 minutes. Infusion sets must contain a 0.2 micron in-line filter. MEDI-551 will be administered on days 1, 8, 15, and 22 of cycle 1, then 4mg/kg IV on day1 of cycles 2 through 12. Treatment may be stopped earlier if there is unacceptable toxicity, development of Grade 3 or 4 graft-versus-host disease (GVHD), documentation of disease progression, or patient withdrawal for other reasons.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy